Clinical Trials on Advanced in Russian Federation

Total 95 results

AstraZeneca

Completed

Study of AZD8931 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Russian Federation, Germany
MelanomaPRO, Russia

Recruiting

Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice (FORA)

Advanced Melanoma

Russian Federation
Blokhin's Russian Cancer Research Center
Russian Society of Clinical Oncology

Completed

Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. (ATLANT)

Metastatic Disease | HR+/HER2- Breast Cancer | Аdvanced Disease

Russian Federation
Pfizer
Medivation, Inc.

Completed

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Russian Federation, Hungary, Moldova, Republic of, Poland
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Advanced Malignancies

United Kingdom, Denmark, Hungary, Russian Federation
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy (LOTOS)

Advanced or Metastatic NSCLC

Russian Federation
Novartis Pharmaceuticals

Recruiting

A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia (ValerEE)

HR+HER2- Advanced Breast Cancer

Russian Federation
Moscow Clinical Scientific Center
IRCCS San Raffaele; Istanbul University; University of Belgrade; University of... and other collaborators

Unknown

Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer (PAC-MAIN)

Pancreatic Cancer | Malnutrition | Chemotherapy | Exocrine Pancreatic Insufficiency | Metastatic Pancreatic Cancer | Locally Advanced Malignant Neoplasm

Turkey, Italy, Romania, Russian Federation, Serbia, Spain
AstraZeneca

Completed

Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

Advanced Breast Cancer

Russian Federation, Ukraine, Czech Republic
AB Science

Completed

Masitinib Plus Gemcitabine in Pancreatic Cancer

Locally Advanced or Metastatic Pancreatic Cancer

France, Belgium, Greece, India, Russian Federation, Slovakia, Tunisia, Ukraine
AstraZeneca

Completed

LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer (LINE)

Local Advanced or Metastatic Postmenopausal Breast Cancer

Russian Federation
AstraZeneca

Completed

Non-Interventional Study PREVENT (PREVENT)

Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients

Russian Federation
Mologen AG

Completed

Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma (IMPACT)

Advanced Colorectal Carcinoma

United Kingdom, Germany, Austria, Czech Republic, France, Russian Federation
Astellas Pharma Europe B.V.

Completed

An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation

Advanced Prostate Carcinoma

Russian Federation
Biocad

Recruiting

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Advanced Melanoma

Russian Federation, Belarus
Bayer

Completed

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Poland, China, Slovakia, France, Germany, Indonesia, Korea, Republic of, Sweden, Philippines, Austria, Colombia, Czech Republic, Mexico, Russian Federation, Slovenia, Argentina, Greece, Netherlands
AGC Biologics S.p.A.

Completed

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (NGR019)

Advanced Malignant Pleural Mesothelioma

Italy, Germany, Russian Federation
Eisai Inc.
Quintiles, Inc.

Terminated

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Advanced or Metastatic Solid Tumors | Previously Untreated Gastric Cancer

United States, Russian Federation, United Kingdom, Ukraine
Pfizer

Active, not recruiting

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Non-small-cell Lung Cancer | Advanced Malignancies

China, Korea, Republic of, Taiwan, Japan, Russian Federation, Ukraine
Eli Lilly and Company

Withdrawn

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Metastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung Cancer

Italy, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies (CheckMate 908)

Various Advanced Cancer

United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, United Kingdom
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

United States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Merck Sharp & Dohme LLC
AstraZeneca

Recruiting

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Advanced Solid Neoplasms

United States, Argentina, Australia, Canada, Colombia, Denmark, France, Guatemala, Ireland, Israel, Japan, Korea, Republic of, Mexico, Peru, Romania, Russian Federation, Spain, Turkey, United Kingdom, Switzerland, Italy
Bristol-Myers Squibb

Completed

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

France, Poland, Russian Federation, Taiwan, United States, Hong Kong, Spain, Germany, Italy, Japan, Korea, Republic of, Singapore
AstraZeneca

Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)

Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC)

Russian Federation
Bayer

Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

United States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
Amgen

Terminated

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

Adenocarcinoma of the Pancreas | Locally Advanced | Unresectable

Spain, Belgium, Denmark, Poland, United States, Korea, Republic of, Russian Federation, Austria, Portugal, United Kingdom, Germany, Hungary, Czech Republic
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)

Advanced Cancer

Spain, Argentina, United States, Korea, Republic of, Taiwan, Belgium, Romania, Germany, United Kingdom, Australia, Brazil, Canada, China, Czechia, Denmark, France, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, ... and more
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Locally Advanced or Metastatic and Unresectable HCC

United States, Spain, China, Taiwan, Belgium, Korea, Republic of, Italy, Hong Kong, Russian Federation, Ukraine, Turkey, Poland, Germany
Biocad

Recruiting

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (OCTAVA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma Advanced

India, Russian Federation, Belarus
Agenus Inc.

Suspended

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Advanced Melanoma

United States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
Novartis Pharmaceuticals

Completed

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (RADIANT-4)

Neuroendocrine Tumors | Advanced NET of GI Origin | Advanced NET of Lung Origin

United States, Colombia, Italy, Taiwan, United Kingdom, Belgium, Czechia, Germany, Japan, Saudi Arabia, Canada, Netherlands, Spain, Korea, Republic of, Lebanon, Austria, China, Greece, South Africa, Thailand, Hungary, Turkey, Poland, ... and more
ImmunityBio, Inc.

Completed

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma

United States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
Hoffmann-La Roche

Terminated

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers

Korea, Republic of, France, Spain, Belgium, United Kingdom, Singapore, Israel, Russian Federation, Taiwan, Switzerland, Turkey, United States, New Zealand, Poland, Germany
R-Pharm

Completed

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Advanced/Metastatic Non-Small Cell Lung Cancer

Germany, Korea, Republic of, Russian Federation, Taiwan, Australia, Italy, France, United States, Argentina, Spain
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Advanced Gastric Cancer | Gastro-esophageal Junction Cancer

United States, France, Italy, Taiwan, United Kingdom, Turkey, Germany, Singapore, Australia, Russian Federation, Korea, Republic of, Switzerland, Netherlands, Canada
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)

Various Advanced Cancer

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Romania, Russian Federation and more
Novartis Pharmaceuticals

Completed

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Advanced Endometrial Cancer

Belgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, Australia, Brazil, Czech Republic, Russian Federation, Singapore
Rainier Therapeutics

Terminated

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-22)

Urinary Bladder Disease | Locally Advanced or Metastatic Urothelial Cell Carcinoma | Urological Diseases

United States, Spain, Belgium, France, Germany, Italy, Korea, Republic of, Turkey, Hungary, Netherlands, Serbia, Poland, Russian Federation, Sweden, Moldova, Republic of, Denmark, Ukraine
H3 Biomedicine Inc.
Eisai Inc.

Completed

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Liver Neoplasms | Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | Liver Cancer | Hepatic Cancer | Hepatic Carcinoma

France, United States, Belgium, Spain, Taiwan, Korea, Republic of, Russian Federation, Canada, Italy, Singapore, United Kingdom
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Advanced Colorectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States, Australia, Belgium, Brazil, Canada, Czech Republic, Greece, Korea, Republic of, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2)

Advanced ER-Positive HER2-Negative Breast Cancer

United States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
Genzyme, a Sanofi Company

Active, not recruiting

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment (88)

Medullary Thyroid Cancer | Locally Advanced or Metastatic Medullary Thyroid Cancer

Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, Germany, Greece, India, Israel, Italy, Korea, Republic of, Poland, Russian Federation, Sweden, United Kingdom
Pfizer

Terminated

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

United States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
Pfizer

Active, not recruiting

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Ovarian Cancer | NSCLC | Solid Tumors | Urothelial Cancer | Advanced Malignancies

Hungary, Spain, United States, Canada, Taiwan, Japan, Serbia, Italy, New Zealand, Australia, Mexico, Russian Federation, United Kingdom, France, Korea, Republic of, Belgium, Poland, Denmark, Israel
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648)

Various Advanced Cancer

United States, Japan, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, France, Hong Kong, Italy, Korea, Republic of, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Singapore, Spain, ... and more
ImmunityBio, Inc.

Completed

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

United States, Spain, Denmark, Israel, Canada, Australia, Hungary, Chile, France, Italy, Netherlands, Poland, Russian Federation
Solvay Pharmaceuticals

Completed

SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

Advanced Stage Parkinson's Disease

Argentina, United States, Brazil, Bulgaria, Canada, Chile, Colombia, Latvia, Lithuania, Peru, Russian Federation, Ukraine

Clinical Trials on Advanced in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations